Search results for "Lupus erythematosus"

showing 10 items of 140 documents

SPARC regulation of PMN clearance protects from pristane-induced lupus and rheumatoid arthritis

2021

Summary The secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein with unexpected immunosuppressive function in myeloid cells. We investigated the role of SPARC in autoimmunity using the pristane-induced model of lupus that, in mice, mimics human systemic lupus erythematosus (SLE). Sparc−/− mice developed earlier and more severe renal disease, multi-organ parenchymal damage, and arthritis than the wild-type counterpart. Sparc+/- heterozygous mice showed an intermediate phenotype suggesting Sparc gene dosage in autoimmune-related events. Mechanistically, reduced Sparc expression in neutrophils blocks their clearance by macrophages, through defective delivery of don'…

0301 basic medicineScienceImmunologyArthritis02 engineering and technologySettore MED/08 - Anatomia Patologicamedicine.disease_causeArticleAutoimmunityPathogenesis03 medical and health sciencesmedicineSettore MED/05 - Patologia ClinicaMacrophageMolecular physiologyMultidisciplinarySystemic lupus erythematosusbusiness.industryQMatricellular proteinDendritic cell021001 nanoscience & nanotechnologymedicine.diseaseBiological sciences Immunology Molecular physiologyBiological sciences030104 developmental biologyRheumatoid arthritisCancer research0210 nano-technologybusinessiScience
researchProduct

2021

Background: Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease and patients are under an increased risk for cardiovascular (CV) events and mortality. The increased CV risk for patients with SLE seems to be caused by a premature and accelerated atherosclerosis, attributable to lupus-specific risk factors (i.e., increased systemic inflammation, altered immune status), apart from traditional CV risk factors. To date, there is no established experimental model to explore the pathogenesis of this increased CV risk in SLE patients. Methods: Here we investigated whether MRL-Faslpr mice, which develop an SLE-like phenotype, may serve as a model to study lupus-mediated v…

0301 basic medicineSystemic inflammationCatalysisInorganic ChemistryPathogenesis03 medical and health sciences0302 clinical medicineimmune system diseasesmedicinePhysical and Theoretical Chemistryskin and connective tissue diseasesInterleukin 6Molecular BiologySpectroscopy030203 arthritis & rheumatologyAutoimmune diseaseKidneySystemic lupus erythematosusbiologyVascular diseasebusiness.industryOrganic ChemistryGeneral MedicineArteriosclerosismedicine.diseaseComputer Science Applications030104 developmental biologymedicine.anatomical_structureImmunologybiology.proteinmedicine.symptombusinessInternational Journal of Molecular Sciences
researchProduct

The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts’ Consensus

2021

International audience; Autoimmune diseases (AIDs) share similar serological, clinical, and radiological findings, but, behind these common features, there are different pathogenic mechanisms, immune cells dysfunctions, and targeted organs. In this context, multiple lines of evidence suggest the application of precision medicine principles to AIDs to reduce the treatment failure. Precision medicine refers to the tailoring of therapeutic strategies to the individual characteristics of each patient, thus it could be a new approach for management of AIDS which considers individual variability in genes, environmental exposure, and lifestyle. Precision medicine would also assist physicians in ch…

0301 basic medicinerheumatoid arthritismedicine.medical_specialtyantiphospholipid syndrome; precision medicine; primary sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosis; consensus; humans; precision medicine; autoimmune diseases; lupus erythematosus systemic; sjogren's syndromeConsensusspondyloarthritidesystemic sclerosisImmunologysystemic lupus erythematosuSjogren's Syndrome.Context (language use)Consensuprimary Sjogren's syndromeAutoimmune DiseaseTreatment failureAutoimmune DiseasesNOEfficacy03 medical and health sciences0302 clinical medicineprimary Sjogren’s syndromeAcquired immunodeficiency syndrome (AIDS)systemic lupus erythematosusmedicineImmunology and AllergyHumansLupus Erythematosus SystemicIn patientIntensive care medicineAdverse effect030203 arthritis & rheumatologybusiness.industryPrecision medicinePrecision medicine; antiphospholipid syndrome; primary Sjogren’s syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisEnvironmental exposurerheumatoid arthritimedicine.diseasePrecision medicineantiphospholipid syndrome; Precision medicine; primary Sjogren's syndrome; rheumatoid arthritis; spondyloarthritides; systemic lupus erythematosus; systemic sclerosisspondyloarthritides3. Good health030104 developmental biologySjogren's Syndrome[SDV.IMM]Life Sciences [q-bio]/Immunologybusinesssystemic sclerosiantiphospholipid syndromeHuman
researchProduct

Interleukin-9 and T helper type 9 cells in rheumatic diseases

2016

Summary Interleukin (IL)-9 is a 28-30 kDa monomeric glycosylated polypeptide belonging to the IL-7/IL-9 family of proteins that bind to a composite receptor consisting of the private receptor IL-9R and the IL-2 receptor, gamma (IL-2RG), a common gamma subunit shared by the receptors of many different cytokines. The IL-9R is expressed widely and IL-9 impacts a number of effector cells, such as effector T cells, B cells, innate lymphoid cells, mast cells, polymorphonuclear cells, epithelial cells and smooth muscle cells, playing an important role in regulating inflammatory immunity. The critical role of IL-9 in promoting cellular and humoral immune responses makes it an important focus of pot…

0301 basic medicinerheumatoid arthritispsoriatic arthritisystemic sclerosisSLEReview ArticleIL-9; psoriatic arthritis; rheumatoid arthritis; SLE; systemic sclerosis; Th9 cells; vasculitis; Immunology and Allergy; ImmunologyTh9 cellsvasculitisArthritis RheumatoidInterleukin 210302 clinical medicineT-Lymphocyte SubsetsTh9 cellIL-9; SLE; Th9 cells; psoriatic arthritis; rheumatoid arthritis; systemic sclerosis; vasculitisLupus Erythematosus SystemicMedicineImmunology and AllergyIL-2 receptorpsoriatic arthritisB-LymphocytesInterleukin-17Innate lymphoid cellT-Lymphocytes Helper-InducerAcquired immune systemInterleukin 10vasculitiInterleukin 12systemic sclerosiSignal TransductionImmunologyAutoimmune Diseases03 medical and health sciencesRheumatic DiseasesAnimalsHumans030203 arthritis & rheumatologyScleroderma Systemicbusiness.industryArthritis PsoriaticInterleukin-9rheumatoid arthritiIL-9Immunity HumoralInterleukin 33Settore MED/16 - Reumatologia030104 developmental biologyCTLA-4Immunologybusiness
researchProduct

AORTIC STIFFNESS IS INCREASED IN NORMOTENSIVE PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS Abstracts from the 17th National Congress of the Italian Soc…

2019

Introduction: Patients with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular (CV) events. A marker of early vascular aging (EVA) is aortic pulse wave velocity (aPWV) which is a measure of arterial stiffness. Aim: To evaluate aPWV and the prevalence of EVA in a group of normotensive patients with SLE and to compare these values with those obtained in age- and gender-matched control subjects. Method: Aortic PWV was measured by a validated oscillometric device (Arteriograph). EVA was identified when the age-adjusted z-score of aPWV exceeded ? 1.96 (EVA1). The aPWV z-score was calculated using the ratio ‘‘Observed PWV–Predicted PWV/SD Predicted’’ and we obt…

AORTIC STIFFNESS - systemic lupus erythematosus - EARLY VASCULAR AGING
researchProduct

Ranking the impact of human health disorders on gut metabolism: Systemic lupus erythematosus and obesity as study cases

2015

Multiple factors have been shown to alter intestinal microbial diversity. It remains to be seen, however, how multiple collective pressures impact the activity in the gut environment and which, if any, is positioned as a dominant driving factor determining the final metabolic outcomes. Here, we describe the results of a metabolome-wide scan of gut microbiota in 18 subjects with systemic lupus erythematosus (SLE) and 17 healthy control subjects and demonstrate a statistically significant difference (p < 0.05) between the two groups. Healthy controls could be categorized (p < 0.05) based on their body mass index (BMI), whereas individuals with SLE could not. We discuss the prevalence of SLE c…

AdultAutoimmunityGut floramedicine.disease_causeArticleAutoimmunityBody Mass IndexmedicineHomeostasisHumansLupus Erythematosus SystemicMetabolomicsClinical significanceMicrobiomeObesityMultidisciplinaryLupus erythematosusbiologyMicrobiotaCase-control studyMiddle Agedmedicine.diseasebiology.organism_classificationObesityN-Acetylneuraminic AcidGastrointestinal TractCase-Control StudiesImmunologyMetabolomeFemaleMicrobiomeBody mass indexMetabolic Networks and PathwaysScientific Reports
researchProduct

The Use of Frozen-Thawed Platelet-Derived Phospholipids as a Confirmatory Test for the Diagnosis of Lupus Anticoagulants. Comparison with Two Commerc…

1999

Lupus anticoagulants (LAs) belong to acquired circulating anticoagulants interfering with phospholipid-dependent coagulation tests. Owing to the remarkable variability among patients, SSC guidelines recommend more than one test to detect and confirm the presence of LAs. However, this is an expensive procedure and greatly raises the work load of the laboratory. A standardised platelet-derived phospholipid preparation was obtained and platelet neutralisation (PNP) procedures with APTT and DRVVT reagents were performed on plasmas from 16 patients with LAs and from 41 control subjects. In comparisons, STAclot-PNP and DVVconfirm clotting assays were conducted. PNP by using APTT or DRVVT reagents…

AdultBlood PlateletsMaleinorganic chemicalsAdolescentmedicine.drug_classCoefficient of variationCoagulation testingHumansMedicineheterocyclic compoundsPlateletPhospholipidsAgedBlood coagulation testCryopreservationLupus anticoagulantChromatographySystemic lupus erythematosusbusiness.industryAnticoagulantHematologyMiddle Agedmedicine.diseaseControl subjectsenzymes and coenzymes (carbohydrates)Freeze DryingLupus Coagulation InhibitorImmunologyFemaleBlood Coagulation TestsbusinessThrombosis Research
researchProduct

RDW in patients with systemic lupus erythematosus. Influence of anaemia and inflammatory markers

2013

Red blood cell distribution width (RDW) is a routine parameter that reflects size variations in erythrocytes. High RDW has been associated with cardiovascular events and inflammatory diseases. However, no studies evaluating the association of RDW with systemic lupus erythematosus (SLE) have been published. We aimed to explore the association of RDW with inflammatory markers in SLE. As SLE is often associated with anaemia, we considered this factor in order to know whether RDW is related with inflammation, anaemia or both in SLE. The study included 105 SLE patients (7 men, 98 women; aged 15-73 years) and 105 controls (9 men, 96 women; aged 18-71 years). Patients were divided according to ana…

AdultErythrocyte IndicesMalemedicine.medical_specialtyAdolescentPhysiologyInflammationFibrinogenErythrocyte aggregationGastroenterologyYoung Adultimmune system diseasesPhysiology (medical)Internal medicinemedicineHumansLupus Erythematosus SystemicIn patientYoung adultskin and connective tissue diseasesAgedRetrospective StudiesInflammationLupus erythematosusbusiness.industryAnemiaRetrospective cohort studyRed blood cell distribution widthHematologyMiddle Agedmedicine.diseaseImmunologyFemalemedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugClinical Hemorheology and Microcirculation
researchProduct

ProC® Global Assay in the Evaluation of Women with History of Severe Preeclampsia or HELLP Syndrome

2003

Preeclampsia/HELLP syndrome has been associated with a high incidence of defects in the protein C pathway and increased anticardiolipin-antibodies/lupus anticoagulants. It is also apparent that thrombophilia is responsible for other pregnancy complications, such as recurrent spontaneous abortion, fetal growth restriction, intrauterine fetal death, and abruptio placentae. ProC® Global is a new global clotting assay designed to evaluate the abnormalities in the protein C anticoagulant pathway. It is based on the ability of endogenous activated protein C, generated by activation of protein C by Protac®, to prolong an activated partial thromboplastin time. A total of 61 patients with a history…

AdultHELLP Syndromemedicine.medical_specialtyHELLP syndrome030204 cardiovascular system & hematologyThrombophiliaSensitivity and SpecificityGastroenterologyProtein SPreeclampsia03 medical and health sciences0302 clinical medicinePre-EclampsiaPregnancyInternal medicinemedicineHumansThrombophilia030212 general & internal medicineBlood coagulation testSystemic lupus erythematosusmedicine.diagnostic_testbiologybusiness.industryHematologyGeneral Medicinemedicine.diseaseCase-Control StudiesImmunologybiology.proteinFemaleBlood Coagulation TestsReagent Kits DiagnosticbusinessBiomarkersProtein CProtein Cmedicine.drugPartial thromboplastin timeClinical and Applied Thrombosis/Hemostasis
researchProduct

The relations of quality of life in patients with lupus erythematosus: Regression models versus qualitative comparative analysis

2019

Lupus erythematosus (LE) is an autoimmune disease that can have negative repercussions on the quality of life (QL) of those who suffer from it. The QL can be influenced by socio-demographic factors are related to the disease itself.To analyse the associative power of socio-demographic (age and sex) and medical variables (type of lupus, diagnostic time and symptomatically associated with lupus) on the QL in patients with lupus by comparing linear relations models and models based on comparative qualitative fuzzy analysis.This is a retrospective cross-sectional design.The sample consisted of 161 patients (88.4% female) diagnosed with LE between the ages of 18-66 years.Data were collected betw…

AdultMaleAdolescentDiseaseYoung Adult03 medical and health sciences0302 clinical medicineRisk groupsFuzzy LogicQuality of lifeHumansLupus Erythematosus SystemicMedicineIn patient030212 general & internal medicineQualitative ResearchGeneral NursingAgedRetrospective StudiesSystemic lupus erythematosusLupus erythematosus030504 nursingbusiness.industryQualitative comparative analysisRegression analysisMiddle Agedmedicine.diseaseCross-Sectional StudiesQuality of LifeRegression AnalysisFemale0305 other medical sciencebusinessClinical psychologyJournal of Advanced Nursing
researchProduct